Patients with newly diagnosed cerebral gliomas, recurrent cerebral gliomas and brain metastases.
Conditions
Brief summary
The primary endpoint is the agreement of the diagnosis of tumour size and tracer distribution in FET PET with FACBC PET in the examined patients based on consensus voting in the classification categories A or B by three examiners. Categories C and D will be assessed as disagreement.
Detailed description
Significant correlation of the tumour-to-brain ratios in FET and FACBC PET., Similar differences of Time-to-peak (TTP) and slope of the time-activity-curve (TAC) of FET and FACBC uptake in highgrade and low-grade gliomas., Similar accuracy of FET and FACBC PET in differentiating tumour progression (TP) and treatment related changes (TRC) in recurrent gliomas and brain metastases., Similar differences of TTP and slope of the TAC of FET and FACBC uptake in TP and TRC in recurrent gliomas and brain metastases.
Sponsors
Eligibility
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the agreement of the diagnosis of tumour size and tracer distribution in FET PET with FACBC PET in the examined patients based on consensus voting in the classification categories A or B by three examiners. Categories C and D will be assessed as disagreement. | — |
Secondary
| Measure | Time frame |
|---|---|
| Significant correlation of the tumour-to-brain ratios in FET and FACBC PET., Similar differences of Time-to-peak (TTP) and slope of the time-activity-curve (TAC) of FET and FACBC uptake in highgrade and low-grade gliomas., Similar accuracy of FET and FACBC PET in differentiating tumour progression (TP) and treatment related changes (TRC) in recurrent gliomas and brain metastases., Similar differences of TTP and slope of the TAC of FET and FACBC uptake in TP and TRC in recurrent gliomas and brain metastases. | — |
Countries
Germany